Silvia Stacchiotti

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota S, Orsenigo M, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15:1096-104 pubmed publisher
    ..The tumor vascular pattern prompted us to use sunitinib malate (SM), a tyrosine kinase inhibitor with antiangiogenic properties...
  2. Stacchiotti S, Pantaleo M, Negri T, Astolfi A, Tazzari M, Dagrada G, et al. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clin Cancer Res. 2016;22:837-46 pubmed publisher
    ..Transcriptional profile of naïve and posttreatment samples pointed the contribution of immune infiltrates in sustaining the response to IM. ..
  3. Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay J, et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res. 2013;3:8 pubmed publisher
    ..Molecular studies are needed to clarify the biologic mechanism(s) underlying the response. ..
  4. Stacchiotti S, Dagrada G, Morosi C, Negri T, Romanini A, Pilotti S, et al. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res. 2012;2:22 pubmed publisher
    ..Sunitinib was increased to 50 mg/day, with evidence of a dimensional response 3 months later. Sunitinib showed antitumor activity in 2 patients with advanced EMCS. Further studies are needed to confirm these preliminary results. ..
  5. Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco F, Gronchi A, et al. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. Eur J Cancer. 2018;106:225-233 pubmed publisher
    ..Responses were better detected with Choi and seen even in patients resistant to other antiangiogenics. Tolerability was good. ..
  6. Stacchiotti S, Tortoreto M, Baldi G, Grignani G, Toss A, Badalamenti G, et al. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. Eur J Cancer. 2014;50:3021-8 pubmed publisher
    ..When administered in patients, pazopanib showed a modest activity in terms of tumour growth stabilisation, observed only in non-dedifferentiated cases. ..
  7. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22:1682-90 pubmed publisher
    ..We confirm the clinical efficacy of sunitinib in ASPS, mediated by PDGFRB, VEGFR2, and RET, which are all expressed in tumor cells. A direct antitumor effect was shown in a short-term cell culture. ..
  8. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9:1286-97 pubmed publisher
    ..SM has antitumor activity in SFT, possibly through a PDGFRB-mediated mechanism, but treatments with IGFIR/insulin receptor and possibly epidermal growth factor receptor inhibitors are worth testing. ..
  9. Urbini M, Indio V, Astolfi A, Tarantino G, Renne S, Pilotti S, et al. Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. Int J Mol Sci. 2018;19: pubmed publisher

More Information

Publications24

  1. Stacchiotti S, Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16:e71-83 pubmed publisher
    ..The consensus reached at that meeting is shown in this position paper. ..
  2. Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, et al. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer. 2015;15:58 pubmed publisher
    ..Thus, manipulation of the immune response may have therapeutic potential for this STS subtype and immunotherapy approaches, can be promising therapeutic options for these patients. ..
  3. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, et al. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. Surg Oncol. 2016;25:125-31 pubmed publisher
  4. Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo M, Negri T, et al. Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. Mol Cancer Res. 2016;14:820-9 pubmed publisher
    ..Chromosome 22q deletion might play a role in FS-DFSP, and p16 loss may convey a poor outcome. EZH2 dysregulation was also found and represents a druggable target. Mol Cancer Res; 14(9); 820-9. ©2016 AACR. ..
  5. Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, et al. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. Ann Surg Oncol. 2016;23:2735-44 pubmed publisher
    ..A clinical benefit was achieved in 56 % of patients receiving sirolimus, which lasted >24 months in four patients. Most patients with pleural effusion did not benefit from sirolimus and had a poor outcome. ..
  6. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer. 2011;129:1761-72 pubmed publisher
    ..In conclusion, DFSP-derived FS maintains the fusion-gene, being sensitive to imatinib. However, responses are short-lasting. Secondary resistance to imatinib is not related to PDGFRB. ..
  7. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009;20:1886-94 pubmed publisher
    ..Imatinib (IM) is active in advanced chordoma. The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma...
  8. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki R, et al. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist. 2018;23:62-70 pubmed publisher
  9. Colia V, Stacchiotti S. Medical treatment of advanced chordomas. Eur J Cancer. 2017;83:220-228 pubmed publisher
  10. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, et al. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. Eur J Cancer. 2017;76:84-92 pubmed publisher
    ..Among additional drugs tested in the PDXs, trabectedin and eribulin were highly effective, providing a rational to test these drugs in D-SFT patients. ..
  11. Stacchiotti S, Casali P, Lo Vullo S, Mariani L, Palassini E, Mercuri M, et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol. 2010;17:211-9 pubmed publisher
    ..Chordoma is a rare tumor, and its natural history is still not well known...
  12. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24:1931-6 pubmed publisher
    ..To report on a prospective, investigator-driven, phase II study on lapatinib in epidermal growth factor receptor (EGFR)-positive advanced chordoma patients...
  13. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart Bosch A, et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012;118:5857-66 pubmed publisher
    ..Choi criteria were better predictors than RECIST in patients who received preoperative chemotherapy alone. ..
  14. Stacchiotti S, Casali P. Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep. 2011;13:323-30 pubmed publisher
    ..However, systemic therapy is needed in patients non-amenable to surgery and/or radiation therapy. We reviewed systemic treatments currently available, and targets possibly druggable in the future in this orphan disease...
  15. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012;30:914-20 pubmed publisher
    ..To explore the antitumor activity of imatinib in patients with advanced platelet-derived growth factor ? (PDGFB)/PDGF receptor ? (PDGFRB)-positive chordomas...